Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial

John Seymour, Andrew Aw, Vincent Ribrag, Guillaume Cartron, Arnon Kater, Ki-Seong Eom, Alan Skarbnik, Alessandra Tedeschi, Malgorzata Wach, Jing-Zhou Hou, Arpad Illes, Batul Suterwala, Jiefen Munley, Ellie John, Toshifumi Fujimori, Jennifer Brown

Blood (2025) 146 (Supplement 1): 2118.

https://doi.org/10.1182/blood-2025-2118

Published: 2025

Journal Articles

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

Jing-Zhou Hou, Rushir Choksi, Gregory Maglinte, Xiaoliang Wang, Anna Rui, Beverly Chigarira, Lindsay Aton, Melissa Hagan, Lisa Morere, Mike Gart, Rhys Williams, Daniel Ermann

Blood (2025) 146 (Supplement 1): 6317.

https://doi.org/10.1182/blood-2025-6317

Published: 2025

Journal Articles

Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment

Jing-Zhou Hou, Tejvir Singh, Wesley Falconer, Patrick Travis, Olalekan Ajayi, Jason Stinnett, Kyle Kitchen, Anna Rui, Mike Gart, Lisa Kunst, Lindsay Aton, Poras Dave, Doug Kanovsky, Brandon Wang, Prateesh Varughese, Robert Geller, Jeffrey Scott, Rushir Choksi

Blood (2025) 146 (Supplement 1): 7934.

https://doi.org/10.1182/blood-2025-7934

Published: 2025

Journal Articles

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

Blood (2025) 146 (Supplement 1): 6286.

https://doi.org/10.1182/blood-2025-6286

Published: 2025

Journal Articles

Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use

Rushir Choksi, Aliakbar Dadla, Thomas Weart, Brian Mulherin, Taral Patel, Fred Kudrik, Tejvir Singh, Steven Champaloux, John Li, Anna Rui, Gino Cioffi, Don Parris, Mike Gart, Janet Donegan, Lisa Morere, Lisa Kunst, Lindsay Aton, Jeffrey Scott, Jing-Zhou Hou

Blood (2025) 146 (Supplement 1): 6285.

https://doi.org/10.1182/blood-2025-6285

Published: 2025

Journal Articles

Kpg-818, a novel cereblon (CRBN) modulator, in patients with hematological malignancies: Results of a Phase 1, open-label, multiple ascending dose study

Aaron Rosenberg, Cristiana Costa, Nirav Shah, Ahmad Mattour, Eudardo Miranda, Jing-Zhou Hou, Chuansheng Ge, Qiaoyun Yu, Juanjuan Wang, Huaping Wei, Lizhi Zhao, Yao Wang

Blood (2025) 146 (Supplement 1): 5809.

https://doi.org/10.1182/blood-2025-5809

Published: 2025

Journal Articles

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy

Jing-Zhou Hou, Rushir Choksi, Gregory Maglinte, Xiaoliang Wang, Anna Rui, Beverly Chigarira, Lindsay Aton, Melissa Hagan, Lisa Morere, Rhys Williams, Daniel Ermann

Blood (2025) 146 (Supplement 1): 8041.

https://doi.org/10.1182/blood-2025-8041

Published: 2025

Journal Articles

Evolutionary divergence of polymorphic HLA residues predicts clinical outcomes after haploidentical stem cell transplantation in patients with AML

Blood (2025) 146 (Supplement 1): 512.

https://doi.org/10.1182/blood-2025-512

Published: 2025

Journal Articles

Real-world incidence of treatment-emergent cardiovascular events among chronic lymphocytic leukemia/small lymphocytic lymphoma patients receiving acalabrutinib or zanubrutinib monotherapy

Jing-Zhou Hou, Rushir Choksi, Anna Rui, Vikram Shetty, Anna Teschemaker, Kathy Wojtas, Steven Champaloux, Dipen Patel, Doug Kanovsky, Jeffrey Scott, Aliakbar Dadla, Daniel Allendorf

Blood (2025) 146 (Supplement 1): 4506.

https://doi.org/10.1182/blood-2025-4506

Published: 2025

Journal Articles

Real-world comparison of treatment outcomes between BCL2i and 2nd generation BTKi therapy in first-line CLL patients

Rushir Choksi, Aliakbar Dadla, Thomas Weart, Brian Mulherin, Taral Patel, Fred Kudrik, Tejvir Singh, Anna Rui, Gino Cioffi, Don Parris, Mike Gart, Janet Donegan, Lisa Morere, Lisa Kunst, Lindsay Aton, Poras Dave, Doug Kanovsky, Jeffrey Scott, Jing-Zhou Hou

Blood (2025) 146 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2025-4505

Published: 2025

Journal Articles

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Blood (2025) 146 (Supplement 1): 5514.

https://doi.org/10.1182/blood-2025-5514

Published: 2025

Journal Articles

SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphoma

Chan Cheah, Monique Menzies Wojtowicz, Catherine Thieblemont, Martin Hutchings, Prof. Dr. Max S Topp, Won-Seog Kim, Dai Maruyama, Azadeh Shohoudi, Robin Lesley, Wendy Chang, Marlene Zuraek, Mihail Obrocea, Jing-Zhou Hou

Blood (2025) 146 (Supplement 1): 3747.

https://doi.org/10.1182/blood-2025-3747

Published: 2025

Journal Articles

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Blood (2025) 146 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2025-1005

Published: 2025

Journal Articles

Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients

Blood (2024) 144 (Supplement 1): 868.

https://doi.org/10.1182/blood-2024-193681

Published: 2024

Journal Articles

Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 341.

https://doi.org/10.1182/blood-2024-193589

Published: 2024

Journal Articles

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Jing-Zhou Hou, Rushir Choksi, Gregory A. Maglinte, Anupama Vasudevan, Anna Rui, Brandon Wang, Hoa Pham, Ann Lasn, Simon Blanc

Blood (2024) 144 (Supplement 1): 2353.

https://doi.org/10.1182/blood-2024-207760

Published: 2024

Journal Articles

Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton's Tyrosine Kinase Inhibitors (BTKi)

Jing-Zhou Hou, Rushir Choksi, Anupama Vasudevan, Anna Rui, Poras Davé, Mike Gart, Brandon Wang, Prateesh Varughese, Simon Blanc

Blood (2024) 144 (Supplement 1): 3253.

https://doi.org/10.1182/blood-2024-199765

Published: 2024

Journal Articles

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices

Jing-Zhou Hou, Simon Blanc, Gregory A Maglinte, Anupama Vasudevan, Anna Rui, Michael Gart, Hoa Pham, Lindsay Aton, Brandon Wang, Rushir Choksi

Blood (2023) 142 (Supplement 1): 5163.

https://doi.org/10.1182/blood-2023-174915

Published: 2023

Journal Articles

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A. Jonas, Radovan Vrhovac, Pau Montesinos, Jacqueline S. Garcia, David Rizzieri, Michael J Thirman, Stanley Kotey, Jalaja Potluri, Mazaher Dhalla, Vinod Pullarkat

Blood (2023) 142 (Supplement 1): 2886.

https://doi.org/10.1182/blood-2023-182045

Published: 2023

Journal Articles

Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial

Sameh Gaballa, Ranjit Nair, Ryan W Jacobs, Sumana Devata, Seok-Goo Cho, Don A. Stevens, Dok Hyun Yoon, Nirav N. Shah, Denise Brennan, Jason Law, Robert Chen, David Sermer, Robin Lesley, Ben Buelow, Alessandra Forcina, Jing-Zhou Hou

Blood (2023) 142 (Supplement 1): 1662.

https://doi.org/10.1182/blood-2023-174668

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use

Kpg-818, a novel cereblon (CRBN) modulator, in patients with hematological malignancies: Results of a Phase 1, open-label, multiple ascending dose study

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy

Evolutionary divergence of polymorphic HLA residues predicts clinical outcomes after haploidentical stem cell transplantation in patients with AML

Real-world incidence of treatment-emergent cardiovascular events among chronic lymphocytic leukemia/small lymphocytic lymphoma patients receiving acalabrutinib or zanubrutinib monotherapy

Real-world comparison of treatment outcomes between BCL2i and 2nd generation BTKi therapy in first-line CLL patients

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphoma

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients

Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton's Tyrosine Kinase Inhibitors (BTKi)

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only